Lab Corp (LH) Offering Possible 12.36% Return Over the Next 30 Calendar Days

Lab Corp's most recent trend suggests a bullish bias. One trading opportunity on Lab Corp is a Bull Put Spread using a strike $250.00 short put and a strike $230.00 long put offers a potential 12.36% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $250.00 by expiration. The full premium credit of $2.20 would be kept by the premium seller. The risk of $17.80 would be incurred if the stock dropped below the $230.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Lab Corp is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Lab Corp is bullish.

The RSI indicator is at 68.4 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Lab Corp

UPDATE 2-CVS to offer three over-the-counter COVID-19 tests for use at home
Mon, 19 Apr 2021 13:49:57 +0000
CVS Health Corp said on Monday it would offer three over-the-counter COVID-19 tests at its drugstores as well as online starting this week, expanding access to home testing in the United States. CVS said it was offering tests from Australian diagnostic test maker Ellume, Abbott Laboratories and LabCorp that do not require a prescription and can be used by individuals with or without symptoms. Abbott's BinaxNOW antigen self-test, which received U.S. regulatory nod last month, and LabCorp's test kits would be available at some pharmacy stores and online, CVS said.

CVS to offer three over-the-counter COVID-19 tests for use at home
Mon, 19 Apr 2021 13:00:01 +0000
CVS Health Corp said on Monday it would offer three over-the-counter COVID-19 tests at its drugstores as well as online, expanding access to home testing as the United States speeds up its vaccine rollout. The company said the tests include a home test by Australian diagnostic test maker Ellume, Abbott Laboratories' BinaxNOW antigen self-test and LabCorp's home collection kits, all of which do not require a prescription, and can be used by individuals with or without symptoms. CVS is the first drug retailer to offer Ellume's test, the company said, adding that the test will be available in select pharmacy locations in Rhode-Island and Massachusetts from this week, and at CVS.com and most pharmacy stores by the end of May.

A Trio of Health Care Stock Picks
Sun, 18 Apr 2021 22:07:30 +0000
Cigna tops the list

Labcorp to Webcast Its Annual Meeting of Shareholders
Fri, 16 Apr 2021 11:01:00 +0000
Labcorp (NYSE: LH), a leading global life sciences company, today announced that its Annual Meeting of Shareholders will be webcast live beginning May 12, at 9:00 a.m. ET via the company website at www.Labcorp.com. An archived replay of the webcast will be available for one year.

10 Best Stocks To Buy According To Billionaire Larry Robbins
Sat, 03 Apr 2021 14:56:28 +0000
In this article we presented 10 best stocks to buy according to billionaire Larry Robbins. Click to skip our detailed discussion on Robbins’ investment strategy and see 5 Best Stocks To Buy According To Billionaire Larry Robbins. Larry Robbins is an American billionaire and hedge fund manager who founded Glenview Capital Management in 2000. As […]

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.